MDxHealth Signs on FedMed, ACPN for Increased Access to ConfirmMDx Test | GenomeWeb

NEW YORK (GenomeWeb News) – MDxHealth today announced it signed agreements with health insurance providers FedMed and America's Choice Provider Network, extending access to the company's ConfirmMDx prostate cancer test to 50 million additional lives.

FedMed has 40 million covered lives, while ACPN has 11.2 million lives, MDxHealth said. The firm said that more than 130 million covered lives now have access to the ConfirmMDx test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.